AAVantgarde Bio to Present Pioneering Gene Therapy Findings at FLORetina Annual Meeting
AAVantgarde Bio, a leading biotechnology firm in Italy, will present groundbreaking findings from its LUCE-1 clinical study at the FLORetina Annual Meeting on December 7, 2024. The study focuses on a novel dual AAV gene therapy for treating advanced retinitis pigmentosa due to Usher syndrome 1B, marking a significant advancement in ophthalmology. Prof. Francesca Simonelli will discuss the safety results from initial subjects, highlighting the potential of innovative gene therapies in inherited retinal disease treatment.
HI-Bio™ Receives Orphan Drug Designation for Felzartamab Targeted Therapy
HI-Bio™ has received Orphan Drug Designation from the FDA for felzartamab, a targeted therapy for antibody-mediated rejection in kidney transplant recipients. This designation is a significant milestone in addressing the critical unmet medical need for AMR, with potential breakthrough implications. The Orphan Drug Designation qualifies HI-Bio for certain development incentives, expected to accelerate the development of felzartamab and enhance the company’s ability to bring this innovative therapy to patients in need.